429P - Afatinib in the first line therapy of EGFR mutation positive adenocarcinoma of lung: Single institute experience

Abstract

Background: Afatinib provide progression-free survival benefit compared to platinum-based chemotherapy in patients with non-small cell lung cancer harboring epidermal growth factor receptor-activating mutation. Therefore, we conducted this retrospective study to note the efficacy of afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer. Methods: We conducted this retrospective study at a single medical center in Taiwan from June 01, 2014 to December 31, 2016. We used the Kaplan-Meier method to estimate survival. Results: Total 56 patients diagnosed with stage IIIb and IV non-small cell lung cancer in the study period. The median duration of follow-up for progression-free survival was 11 months. The median progression-free survival was 20.6 months. Progression-free survival was significantly longer in the patients who had L858R mutation, good performance status, and adverse effect of afatinib had better PFS. Age, gender, smoking status, decreased dosage of afatinib would not comprised the efficancy. Conclusions: Afatinib had significant benefits in progression-free survival in non-small smallcell lung cancers harboring EGFR-activating mutations. Patients who had L858R mutation, performance status of ECOG PS 0∼1, and adverse events had better survival. Legal entity responsible for the study: This is a study without legal entity responsible for the governance, coordination and running of the study. Funding: None Disclosure: All authors have declared no conflicts of interest.